Hepatocellular carcinoma in the context of chronic hepatitis C infection: pathogenesis, diagnosis and therapeutic advances

Supreet Kumar

doi:10.18203/2349-2902.isj20262498

Authors

Supreet Kumar Department of Surgical Gastroenterology and GI Oncosurgery, Medanta Hospital, Noida, Uttar Pradesh, India https://orcid.org/0000-0003-4798-9293

DOI:

https://doi.org/10.18203/2349-2902.isj20262498

Keywords:

Hepatocellular carcinoma, Hepatitis C, Direct-acting antivirals, Cirrhosis, Molecular pathogenesis, Advanced imaging, Targeted therapy, Immunotherapy, Precision medicine

Abstract

Hepatocellular carcinoma is one of the most formidable cancers worldwide, and chronic infection with hepatitis C virus (HCV) plays a crucial role in its development. Even though the advent of direct-acting antivirals has greatly improved the rate of viral eradication, the lingering effects of long-term HCV—characterized by ongoing inflammation, advancing fibrosis, and intricate genetic alterations—continue to drive the formation of cancer. Based on my own clinical observations as well as recent scientific findings, this chapter delves deeply into the process by which HCC arises in an HCV-affected liver. I describe the sequential molecular events set off by persistent infection, assess modern imaging and diagnostic techniques (including both tissue-based assessments and liquid biopsy approaches), and review a range of treatment strategies from surgical removal to cutting-edge systemic therapies. In addition, I discuss future possibilities, particularly the potential benefits of precision medicine and the integration of multi-omics data. This review is designed to serve as both a practical resource for healthcare professionals and a catalyst for further research.

Author Biography

Supreet Kumar, Department of Surgical Gastroenterology and GI Oncosurgery, Medanta Hospital, Noida, Uttar Pradesh, India

CONSULTANT

SURGICAL GASTROENTEROLOGY AND GI ONCOLOGY

INDRAPRASTHA APOLLO HOSPITALS

NEW DELHI

References

Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.

El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2006;130(5):1376-85.

Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-74.

Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58(3):593-608.

Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301-14.

Tanaka Y, Kurosaki M, Nishida N, Sugiyama M, Matsuura K, Itoh Y, et al. Epidemiology and risk factors for hepatocellular carcinoma in Japan. J Gastroenterol. 2012;47(5):549-59.

Ioannou GN, Green PK, Berry K. Impact of direct-acting antiviral therapy on hepatocellular carcinoma incidence in patients with chronic hepatitis C. Hepatology. 2018;67(1):138-47.

Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol. 2015;13(12):2140-51.

Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723-50.

Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis. 2010;30(1):3-16.

Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209-18.

Friedman SL. Hepatic fibrosis--overview. Toxicology. 2008;254(3):120-9.

Ray RB, Steele R, Meyer K, Ray R. Hepatitis C virus core protein modulates the Wnt/β-catenin signaling pathway in hepatocarcinogenesis. J Hepatol. 2012;57(4):876-82.

Negro F. Hepatitis C virus and liver cancer: an overview. J Hepatol. 2014;61(1 Suppl):S69-72.

Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49(11):1603-16.

Seki E, Brenner DA. Recent advancement of molecular mechanisms of liver fibrosis. J Hepatol. 2015;62(1 Suppl):S15-24.

Villanueva A. Epigenetic regulation of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12(9):517-28.

Nault JC, Steuer E, Zucman-Rossi J. Genetic mutations in hepatocellular carcinoma: an update. Gastroenterology. 2017;152(7):1480-93.

Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, Shiraishi Y, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet. 2014;46(12):1267-75.

Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317-70.

Dyson J, Jaques B, Chattopadhya S, Lochan R, Graham J, Das D, et al. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014;5(3):211-8

Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect. 2010;118(6):818-24.

Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020-2.

Poynard T, Moussalli J, Munteanu M, Thabut D, Lebray P, Rudler M, et al. Long-term outcome of chronic hepatitis C: relationship between sustained virological response and the risk of liver-related complications. Hepatology. 2005;41(2):354-60.

Wong VW, Wong GL, Tsang SW, Hui AY, Chim AM, Chu SH, et al. Long-term outcome of patients with hepatitis B and C dual infection in an endemic area. J Gastroenterol Hepatol. 2011;26(1):115-20.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236.

Sala M, Forner A, Varela M, Bruix J. Diagnostic and therapeutic algorithms in hepatocellular carcinoma. Abdom Imaging. 2004;29(2):200-8.

Khalili K, Kim TK, Jang HJ, Haider MA, Khan L, Guindi M, et al. Optimization of MRI protocol for hepatic lesion detection and characterization. Semin Liver Dis. 2008;28(2):162-74.

Sterling RK, Jeffers L, Gordon F, Venook AP, Reddy KR, Satapathy SK, et al. Utility of alpha-fetoprotein in the surveillance of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Liver Int. 2012;32(5):748-57.

Lok AS, Sterling RK, Mondala TS, Fontana RJ, Di Bisceglie AM, Sterling RK, et al. Emerging biomarkers for hepatocellular carcinoma. Hepatology. 2010;52(2):660-72.

Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599-616.

Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4(2):439-74.

Singal AG, Pillai A, Tiro J. Early detection, surveillance, and screening of hepatocellular carcinoma. Gastroenterology. 2014;146(7):1582-93.

Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance imaging and alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(5):1376-82.

Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137(3):850-5.

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693-9.

Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394-403.

Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52-60.

de Baere T, Arai Y, Lencioni R, Geschwind JF, Rilling W, Salem R, et al. Treatment of hepatocellular carcinoma with transarterial chemoembolization: a review of the evidence. Cardiovasc Intervent Radiol. 2010;33(2):241-52.

Geschwind JF, Kimbiris D. Interventional radiology in the management of hepatocellular carcinoma. Radiographics. 2002;22(2):e2.

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90.

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163-73.

El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492-502.

Ioannou GN, Green PK, Berry K. Hepatocellular carcinoma risk after sustained virological response in patients with hepatitis C. J Hepatol. 2018;69(4):800-8.

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894-905.

Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011;140(5):1410-26.

Chen M, Li B. Circulating tumor DNA as a liquid biopsy marker for hepatocellular carcinoma. Cancer Lett. 2019;468:1-7.

Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, et al. Prospective classification of oncogenic genomic alterations in patients with advanced hepatocellular carcinoma who received systemic therapy. Hepatology. 2019;70(4):1175-88.

Wakabayashi G, Cherqui D, Geller DA, Buell JF, Kaneko H, Han HS, et al. Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg. 2015;261(4):619-29.

Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1):41-52.

Nkontchou G, Ziol M, Aout M, Labbé C, Roulot D, Bourcier V, et al. Chemoprevention of hepatocellular carcinoma in patients with chronic liver diseases. Expert Rev Gastroenterol Hepatol. 2012;6(5):611-23.

Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al. Adjuvant therapy in hepatocellular carcinoma after curative treatment: current status and future directions. J Hepatol. 2015;62(6):1420-30.

Llovet JM, Schwartz M, Mazzaferro V, Bruix J, Forner A, Reig M, et al. Recurrence after liver transplantation for hepatocellular carcinoma: strategies for prevention and management. Hepatology. 2014;59(6):2326-36.

Kim HS, El-Serag HB. Prognostic models in hepatocellular carcinoma: challenges and opportunities in the era of precision medicine. J Hepatol. 2019;70(1):35-45.

Ioannou GN, Beste LA, Green PK, Singal AG, Torgerson BN, Rich NE, et al. Long-term outcomes after direct-acting antiviral therapy for hepatitis C virus infection: implications for hepatocellular carcinoma surveillance. Hepatology. 2020;71(3):911-23.